Merck Adds 10 Studies To ClinicalTrials.gov, Bringing Total To 13
This article was originally published in The Pink Sheet Daily
Executive Summary
The 10 new Merck entries include three Phase III studies in type 2 diabetes. The company's listings are still relatively few when compared to its peers.
You may also be interested in...
Merck Support For ClinicalTrials.Gov Expansion Does Not Mean Company Will Add Listings
Merck says it prefers to continue to fly below the radar screen with respect to ClinicalTrials.gov unless the law is changed. Merck's response to AMA's clinical trials registry proposal receives national media attention, but the company is an unlikely champion for government-sponsored public trial databases.
HHS Should Track All Rx Clinical Trials, AMA Says
All trials should be registered to ensure results are publicly available, physicians’ association says. Institutional review boards should not approve trials unless they are registered, AMA policy urges.
Another Chance For VALID? Negative Reaction To FDA’s LDT Proposal May Reopen Legislative Talks
All of the witnesses testifying to a House E&C Committee hearing said they preferred the flexibility and targeted enforcement of the VALID Act to FDA’s proposed rule. Will Congress finally be spurred to act?